Analysts' ratings for CytoSorbents (NASDAQ:CTSO) over the last quarter vary from bullish to bearish, as provided by 7 analysts.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $8.71, a high estimate of $10.00, and a low estimate of $1.00. The current average, unchanged from the previous average price target, holds steady.

Understanding Analyst Ratings: A Comprehensive Breakdown

An in-depth analysis of recent analyst actions unveils how financial experts perceive CytoSorbents. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of CytoSorbents's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on CytoSorbents analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

About CytoSorbents

Key Indicators: CytoSorbents's Financial Health

Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.

Revenue Growth: Over the 3 months period, CytoSorbents showcased positive performance, achieving a revenue growth rate of 11.08% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: CytoSorbents's net margin is impressive, surpassing industry averages. With a net margin of -27.1%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): CytoSorbents's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -15.7%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): CytoSorbents's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -4.61% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: CytoSorbents's debt-to-equity ratio surpasses industry norms, standing at 2.06. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

Analyst Ratings: What Are They?

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.